A post-hoc analysis of ACTT-2 (Adaptive COVID-19 Treatment Trial-2) found that the use of a risk profile may more precisely characterize high-risk patients who may benefit from the use of baricitinib. The analysis is published in Annals of Internal Medicine.
Risk profile tool provides clearer insight on hospitalized COVID-19 patients who benefit most from baricitinib treatment
A post-hoc analysis of ACTT-2 (Adaptive COVID-19 Treatment Trial-2) found that the use of a risk profile may more precisely characterize high-risk patients who may benefit from the use of baricitinib. The analysis is published in Annals of Internal Medicine.